Bristol Myers Squibb: A Combined Value And Growth Story

Bristol-Myers Squibb has tumbled from about $75 last year to $56 as of Friday largely due to one failed Phase 3 study in lung cancer. Sometimes this large a price drop in a bull market provides a reason to look for undervaluation. This article suggests ...

Source : https://seekingalpha.com/article/4095703-bristol-myers-squibb-combined-value-growth-story

104
Bristol Myers Squibb: A Combined Value And Growth Story

Source:Forbes

Bristol Myers Squibb: A Combined Value And Growth Story